Editas axes two-thirds of its staff, including its CMO

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

After disappointing trial, Editas puts lead CRISPR drug on h...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial.

Nobel winner Charpentier's CRISPR Therapeutics gets $900m in...

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing therapy for sickle cell dis

First patient dosed in trial of Allergan/Editas’ CRISPR blin...

CRISPR gene editing stocks fall after Editas CEO resigns

Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.